tradingkey.logo

Jupiter Neurosciences Inc

JUNS
查看詳細走勢圖
1.100USD
-0.020-1.79%
收盤 12/19, 16:00美東報價延遲15分鐘
37.72M總市值
虧損本益比TTM

Jupiter Neurosciences Inc

1.100
-0.020-1.79%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.79%

5天

-1.79%

1月

-10.57%

6月

-0.90%

今年開始到現在

-89.72%

1年

-88.69%

查看詳細走勢圖

TradingKey Jupiter Neurosciences Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Jupiter Neurosciences Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名148/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價0.00。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Jupiter Neurosciences Inc評分

相關信息

行業排名
148 / 404
全市場排名
276 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Jupiter Neurosciences Inc亮點

亮點風險
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
估值高估
公司最新PE估值-4.71,處於3年歷史高位
機構減倉
最新機構持股375.55K股,環比減少4.78%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉215.83K股

Jupiter Neurosciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Jupiter Neurosciences Inc簡介

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
公司代碼JUNS
公司Jupiter Neurosciences Inc
CEORosen (Christer)
網址https://jupiterneurosciences.com/

常見問題

Jupiter Neurosciences Inc(JUNS)的當前股價是多少?

Jupiter Neurosciences Inc(JUNS)的當前股價是 1.100。

Jupiter Neurosciences Inc 的股票代碼是什麼?

Jupiter Neurosciences Inc的股票代碼是JUNS。

Jupiter Neurosciences Inc股票的52週最高點是多少?

Jupiter Neurosciences Inc股票的52週最高點是--。

Jupiter Neurosciences Inc股票的52週最低點是多少?

Jupiter Neurosciences Inc股票的52週最低點是--。

Jupiter Neurosciences Inc的市值是多少?

Jupiter Neurosciences Inc的市值是37.72M。

Jupiter Neurosciences Inc的淨利潤是多少?

Jupiter Neurosciences Inc的淨利潤為-2.44M。

現在Jupiter Neurosciences Inc(JUNS)的股票是買入、持有還是賣出?

根據分析師評級,Jupiter Neurosciences Inc(JUNS)的總體評級為買入,目標價格為--。

Jupiter Neurosciences Inc(JUNS)股票的每股收益(EPS TTM)是多少

Jupiter Neurosciences Inc(JUNS)股票的每股收益(EPS TTM)是-0.233。
KeyAI